2
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government for the development of a COVID-19 therapeutics
One documentmore
-
- 2
Mk2 Biotechnolgies new start-up at the Innovation and Start-up Center Biotechnology (IZB) in Martinsried, near Munich, Germany
One documentmore - 2
COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant
One documentmore - 7
Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021
One documentmore - 3
IZB-Start-up AMSilk receives financing of 29 million euros
more - 2
Lindis Biotech develops immunotherapy against bladder cancer
One documentmore -
Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins
One documentmore - 4
ChromoTek and Absolute Antibody Collaborate on Recombinant Engineered Antibodies
One documentmore - 2
A higher omega-3 level apparently protects from dying from COVID-19
One documentmore
- 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
One documentmore KOPIE VON: Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups
One documentmore- 5
Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups
One documentmore - 2
Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools
One documentmore -
KOPIE VON: Inspirational talks form SIRION Biotech, CLS Behring and the German Accelerator at the 13th Biotech Press Lounge at the IZB
One documentmore -
Inspirational talks form SIRION Biotech, CLS Behring and the German Accelerator at the 13th Biotech Press Lounge at the IZB
One documentmore -
The development of a combination drug for immunotherapy and trends of the VC and pharmaceutical branch were introduced at the IZB
One documentmore -
High investor density at the Pitch Day hosted by IZB
One documentmore -
ChromoTek has launched next level of secondary antibodies
One documentmore
1